Iliocaval thrombosis, or thrombosis of the inferior vena cava and iliac veins, is associated
with significant morbidity in the form of limb-threatening compromise from phlegmasia …

Cardiovascular disease, and particularly ischemic heart disease, is a leading cause of
maternal morbidity and mortality in high-income countries. The incidence of acute …

Introduction Real-life data comparing clopidogrel, prasugrel, and ticagrelor for unselected
patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome …

Study Objective To compare the effectiveness and safety of ticagrelor versus prasugrel in
preventing recurrent cardiovascular disease (CVD) and major bleeding events in patients …

The use of prasugrel and ticagrelor as part of dual antiplatelet therapy is increasing in
patients after percutaneous coronary intervention (PCI). Accordingly, we aimed to evaluate …

We sought to investigate the utilization of prasugrel and its association with outcomes
relative to clopidogrel in three typical subgroups of ACS in a real-world setting. Prasugrel is …

Context Ticagrelor was related to bradycardia in DISPERSE-II trial. This risk has been
integrated into the European risk-management plan, and its use is warned in at-risk patients …

Ticagrelor is an oral antiplatelet agent that inhibits cellular adenosine re-uptake by
reversibly binding to the P2Y12 receptors on platelets, with a broad therapeutic window …

Background—Monitoring anticoagulation with activated clotting time (ACT) has been
proposed to reduce ischemic or bleeding events. However, the value of using ACT to …

Aims Hypercholesterolemia is a hazard for increasing susceptibility of the heart to
myocardial infarction (MI) by inducing platelet hyperaggregability. Clopidogrel and prasugrel …